ArticleAnnals of hematology2025
Similar outcomes between HLA-haploid and matched sibling donor hematopoietic stem cell transplantation: a multicenter, retrospective study and severe aplastic anemia transplant-specific prognostic scoring system.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia.Chinese medical journal · 2026Guideline
- Development and validation of a nomogram for early prognostic prediction in childhood aplastic anemia receiving cyclosporine monotherapy.Pediatric research · 2026Article
- Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
In recent years, great progress has been made in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) treatment for hematological malignant diseases because of the advent of novel conditioning regimens, optimized graft manipulation, improved graft-versus-host disease (GVHD) prophylaxis, and advances in supportive care. Recent studies have shown very favorable outcomes in severe aplastic anemia (SAA) patients, with comparable outcomes to those of patients receiving immune suppressive therapy (IST) and allogeneic HSCT from a matched sibling donor (MSD) or matched unrelated donor (MUD). However, most of the previous studies relied on single-center data analyses, and the conditioning regimen, GVHD prophylaxis and supportive care used were relatively singular. We do not know whether there are differences in the survival of SAA patients after haplo-HSCT and MSD-HSCT under conditions involving different transplant centers, conditioning regimens and GVHD prophylaxis. This is a disease-specific, multicenter and retrospective study. We retrospectively studied 156 consecutive patients with SAA who underwent haplo-HSCT or MSD-HSCT at four transplant centers in China. The 5-year overall survival (OS) rate was 87.5% in the haplo-HSCT group and 89.7% in the MSD-HSCT group. The time to hematopoietic reconstitution, incidence of graft versus host disease, and infection and graft failure rates were not significantly different between the groups. Haplo-HSCT achieved outcomes comparable to those of MSD-HSCT for SAA patients. According to the nomogram score, we developed a SAA prognostic scoring system. Haplo-HSCT should be considered an effective alternative for patients with SAA without a matched sibling donor. The SAA transplant-specific prognostic scoring system proposed in this study can conveniently predict the OS for SAA patients following MSD-HSCT or haplo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.